David Schafflick

Publication Activity (10 Years)

Years Active: 2022-2022
Publications (10 Years): 7

Top Topics

Cerebrospinal Fluid

Top Venues

Proceedings of the National Academy of Sciences of the United States of America

This page only lists publications with an associated author ORCID identifier.

Publications

Claudia Janoschka, Maren Lindner, Nils Koppers, Laura Starost, Marie Liebmann, Melanie Eschborn, Tilman Schneider-Hohendorf, Farina Windener, David Schafflick, Ann-Katrin Fleck, Kathrin Koch, Marie Deffner, Anna-Sophie Schwarze, Andreas Schulte-Mecklenbeck, Imke Metz, Sven G Meuth, Catharina C Gross, Gerd Meyer Zu Hörste, Nicholas Schwab, Tanja Kuhlmann, Heinz Wiendl, Monika Stoll, Luisa Klotz
Enhanced pathogenicity of Th17 cells due to natalizumab treatment: Implications for MS disease rebound. Proceedings of the National Academy of Sciences of the United States of America 120 (1) (2022)
Anna M Speicher, Lisanne Korn, Júlia Csatári, Laura Gonzalez-Cano, Michael Heming, Christian Thomas, Christina B Schroeter, David Schafflick, Xiaolin Li, Lukas Gola, Alexander Engler, Thilo Kaehne, Ludovic Vallier, Sven G Meuth, Gerd Meyer Zu Hörste, Stjepana Kovac, Heinz Wiendl, Hans Robert Schöler, Matthias Pawlowski
Deterministic programming of human pluripotent stem cells into microglia facilitates studying their role in health and disease. Proceedings of the National Academy of Sciences of the United States of America 119 (43) (2022)
Claudia Janoschka, Maren Lindner, Nils Koppers, Laura Starost, Marie Liebmann, Melanie Eschborn, Tilman Schneider-Hohendorf, Farina Windener, David Schafflick, Ann-Katrin Fleck, Kathrin Koch, Marie Deffner, Anna-Sophie Schwarze, Andreas Schulte-Mecklenbeck, Imke Metz, Sven G Meuth, Catharina C Gross, Gerd Meyer Zu Hörste, Nicholas Schwab, Tanja Kuhlmann, Heinz Wiendl, Monika Stoll, Luisa Klotz
Enhanced pathogenicity of Th17 cells due to natalizumab treatment: Implications for MS disease rebound. Proceedings of the National Academy of Sciences of the United States of America 120 (1) (2022)
Claudia Janoschka, Maren Lindner, Nils Koppers, Laura Starost, Marie Liebmann, Melanie Eschborn, Tilman Schneider-Hohendorf, Farina Windener, David Schafflick, Ann-Katrin Fleck, Kathrin Koch, Marie Deffner, Anna-Sophie Schwarze, Andreas Schulte-Mecklenbeck, Imke Metz, Sven G Meuth, Catharina C Gross, Gerd Meyer Zu Hörste, Nicholas Schwab, Tanja Kuhlmann, Heinz Wiendl, Monika Stoll, Luisa Klotz
Enhanced pathogenicity of Th17 cells due to natalizumab treatment: Implications for MS disease rebound. Proceedings of the National Academy of Sciences of the United States of America 120 (1) (2022)
Maike Hartlehnert, Anna-Lena Börsch, Xiaolin Li, Miriam Burmeister, Hanna Gerwien, David Schafflick, Michael Heming, I-Na Lu, Venu Narayanan, Jan-Kolja Strecker, Anna Kolz, Anneli Peters, Gregory F Wu, Heinz Wiendl, Lydia M Sorokin, Gerd Meyer Zu Hörste
Bcl6 controls meningeal Th17-B cell interaction in murine neuroinflammation. Proceedings of the National Academy of Sciences of the United States of America 118 (36) (2022)
Claudia Janoschka, Maren Lindner, Nils Koppers, Laura Starost, Marie Liebmann, Melanie Eschborn, Tilman Schneider-Hohendorf, Farina Windener, David Schafflick, Ann-Katrin Fleck, Kathrin Koch, Marie Deffner, Anna-Sophie Schwarze, Andreas Schulte-Mecklenbeck, Imke Metz, Sven G Meuth, Catharina C Gross, Gerd Meyer Zu Hörste, Nicholas Schwab, Tanja Kuhlmann, Heinz Wiendl, Monika Stoll, Luisa Klotz
Enhanced pathogenicity of Th17 cells due to natalizumab treatment: Implications for MS disease rebound. Proceedings of the National Academy of Sciences of the United States of America 120 (1) (2022)
Claudia Janoschka, Maren Lindner, Nils Koppers, Laura Starost, Marie Liebmann, Melanie Eschborn, Tilman Schneider-Hohendorf, Farina Windener, David Schafflick, Ann-Katrin Fleck, Kathrin Koch, Marie Deffner, Anna-Sophie Schwarze, Andreas Schulte-Mecklenbeck, Imke Metz, Sven G Meuth, Catharina C Gross, Gerd Meyer Zu Hörste, Nicholas Schwab, Tanja Kuhlmann, Heinz Wiendl, Monika Stoll, Luisa Klotz
Enhanced pathogenicity of Th17 cells due to natalizumab treatment: Implications for MS disease rebound. Proceedings of the National Academy of Sciences of the United States of America 120 (1) (2022)